Day 1 Highlights from ASH 2024: Breakthroughs in Sickle Cell Disease and ITP

Day 1 of ASH 2024 brought exciting advancements in hematology. In this episode, we explore highlights from pivotal trials, including etavopivat’s impact on sickle cell disease, rilzabrutinib’s rapid platelet response in ITP, and hydroxyurea’s benefits for HbSC patients. Hosted by Matt, this podcast offers clear insights into the research shaping tomorrow’s treatments.Love what you hear? Download the Curie app for daily updates and bonus episodes tailored for oncology professionals.

Episode metadata supplied by the publisher feed · Published Dec 9, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

Day 1 Highlights from ASH 2024: Breakthroughs in Sickle Cell Disease and ITP

0:00 5:52

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Curie: Healthcare in Focus?

This episode is 5 minutes long.

When was this Curie: Healthcare in Focus episode published?

This episode was published on December 9, 2024.

Can I download this Curie: Healthcare in Focus episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!